NEW YORK--(BUSINESS WIRE)--Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Isabel Kurth, PhD, Vice President of Research at Rgenix, will present a poster about Rgenix’s RGX-202 program at the 2018 American Association for Cancer Research Annual Meeting. The meeting is scheduled to take place Saturday, April 14 through Wednesday, April 18 in Chicago.
The details of Rgenix’s presentation are as follows:
Event: AACR Annual Meeting 2018
Date: April 18, 2018
Time: 8:00 A.M. - 12:00 P.M. CDT
Description: Poster 5863/10, “RGX-202, a first-in-class small-molecule inhibitor of the creatine transporter SLC6a8, is a robust suppressor of cancer growth and metastatic progression”
Location: Section 39, McCormick Place, 2301 S. King Drive, Chicago, Il. 60616
Dr. Kurth will present data from pre-clinical research of RGX-202, a first-in-class small molecule inhibitor of the creatine transporter SLC6a8.
About Rgenix
Rgenix, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. Rgenix identifies novel cancer targets using a microRNA based target discovery platform originally developed by Rgenix’s scientific co-founders at The Rockefeller University and now exclusively licensed to Rgenix. The company brings together distinguished scientific founders, a seasoned Board, and a leadership team comprised of experienced drug developers. The company is funded by leading biotechnology investors, including Novo A/S, Sofinnova Partners, and Alexandria Venture Investments. For more information, please visit www.rgenix.com.
About RGX-202
RGX-202 is a small molecule that inhibits a novel cancer metabolism pathway involved in supplying energy to cancer cells. The target of RGX-202, SLC6a8, is over-expressed in several prevalent cancer types, including gastrointestinal malignancies. RGX-202 has demonstrated anti-tumor activity in pre-clinical studies, both as a single agent as well as in combination with standard-of-care therapies. IND-enabling studies for RGX-202 have been completed in preparation for clinical development.
